Zangardi, Mark L <br/><br/>
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?  [electronic resource] 

 -  Expert opinion on investigational drugs  Feb 2019 
 - 107-112 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7658 
<br/><br/><label>Standard No.: </label>10.1080/13543784.2019.1555239  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Camptothecin--administration & dosage<br/>Female<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Prognosis<br/>Triple Negative Breast Neoplasms--drug therapy